104 related articles for article (PubMed ID: 2462025)
1. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
Horning SJ; Hoppe RT; Hancock SL; Rosenberg SA
J Clin Oncol; 1988 Dec; 6(12):1822-31. PubMed ID: 2462025
[TBL] [Abstract][Full Text] [Related]
2. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
[TBL] [Abstract][Full Text] [Related]
3. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
Horning SJ; Hoppe RT; Mason J; Brown BW; Hancock SL; Baer D; Rosenberg SA
J Clin Oncol; 1997 May; 15(5):1736-44. PubMed ID: 9164180
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients.
Martinelli G; Cocorocchio E; Saletti PC; Orecchia R; Bernier J; Tradati N; Santoro P; Robertson C; Peccatori FA; Zucca E; Cavalli F
Leuk Lymphoma; 2003 Nov; 44(11):1919-23. PubMed ID: 14738143
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
Bates NP; Williams MV; Bessell EM; Vaughan Hudson G; Vaughan Hudson B
J Clin Oncol; 1994 Feb; 12(2):288-96. PubMed ID: 7509382
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
Press OW; LeBlanc M; Lichter AS; Grogan TM; Unger JM; Wasserman TH; Gaynor ER; Peterson BA; Miller TP; Fisher RI
J Clin Oncol; 2001 Nov; 19(22):4238-44. PubMed ID: 11709567
[TBL] [Abstract][Full Text] [Related]
8. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
9. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
Gobbi PG; Pieresca C; Frassoldati A; Carotenuto M; Di Renzo N; La Sala A; Berté R; Avanzini P; Federico M; Silingardi V; Ascari E
J Clin Oncol; 1996 Feb; 14(2):527-33. PubMed ID: 8636767
[TBL] [Abstract][Full Text] [Related]
10. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
11. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R
J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
[TBL] [Abstract][Full Text] [Related]
13. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
Klimo P; Connors JM
J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
[TBL] [Abstract][Full Text] [Related]
14. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease.
Moody AM; Pratt J; Hudson GV; Smith P; Lamont A; Williams MV
Clin Oncol (R Coll Radiol); 2001; 13(4):262-8. PubMed ID: 11554622
[TBL] [Abstract][Full Text] [Related]
15. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
16. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
17. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
18. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
